J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH HOLDS ITS FIRST ANNUAL DNA LEAF PRECISION ONCOLOGY SYMPOSIUM IN SUINING CITY, SICHUAN, CHINA

All roads led to the Suining city of Sichuan Province, China, on Oct. 10, 2018, as the J. Michael Bishop Institute of Cancer Research (MBICR) inaugurated its DNA Leaf Precision Oncology?Symposium. This annual symposium was specially organized to celebrate the launching of the DNA Leaf logo, which the iconic Apple logo designer, Rob Janoff crafted for the Institute. Through?this annual symposium, MBICR aims to bring regularly a unique set of internationally-renowned researchers, clinicians, and industry executives from around the world to the institute to discuss recent advances, proffer solutions to current challenges, and envision future applications of precision oncology.?

?

The 1st?DNA Leaf Precision Oncology Symposium?was a full-day event jointly organized by MBICR, Suining Central Hospital and Sichuan Society of Hospitals. Seven advisory board members of MBICR flocked in from the US and the UK to grace?the event, which was also attended by a mixed population of the local audience. The local audience at the inaugural?symposium composed of basic cancer researchers, oncologists, pathologists, clinical researchers, hospital presidents, pharmaceutical company executives, and municipal officials.?

?????????????

万博体育 九州 365Opening the scientific session of the symposium, Dr. J. Michael Bishop gave an extensive?lecture on the nature of precision therapy, its origins, prospects, and obstacles. That singular act by Dr. J. Michael Bishop helped to educate the audience on why the symposium was organized and also helped to open the floor for the other experts who spoke at the event. Following Dr. Bishop’s lead, respected experts in the field discussed in detail a variety of hot topics related to precision oncology. The discussions at the event?include?liquid biopsy?(Dr. Na Li, Suining Central Hospital),?personalized treatment of breast cancer guided by patient-derived xenografts?(Dr. Alana Welm, University of Utah),?oncogenes, oncogene addiction and oncoprotein-targeted therapies?(Dr. Dean Felsher, Stanford University; Dr. Dana Aftab, Exelixis; Dr. Steven Chen, Nanjing Medical University; Dr. Scott Kogan, University of California, San Francisco), and?synthetic lethal cancer therapies to drug the otherwise undruggable cancer genome?(Dr. Dun Yang, MBICR).?

?

This symposium presented a unique opportunity which?affords MBICR to?bring together renowned speakers from across the academic, clinical, and biotechnology spectrum to discuss how they were exploring cancer genome for the precision diagnosis and treatment of cancer.?Oncoprotein-targeted therapies have become a mainstay of cancer drug discovery for the past two decades and were a common theme of the symposium. However, Dr. Dun Yang presented synthetic lethal therapies as an alternative approach for the treatment of cancer. According to Dr. Yang, MBICR researchers are striving to discover and develop synthetic lethal therapeutics from plants for the precision treatment of cancer. Dr. Yang explained the importance of the development of synthetic lethal cancer therapies in his presentation.?

The genomic landscape of human tumors is dominated by changes in tumor suppressors, undruggable oncogenes, passenger mutations, and the DNA ploidy. These cancer genome alterations are largely not exploited for the treatment of cancer.?Synthetic lethal therapies are emerging as an approach to drug the undruggable cancer genome, and will greatly broaden the repertoire of targeted therapies. As the majority of cancers do not have high mutation loads to enable their selective elimination by the current immunotherapies, synthetic lethal therapies will likely become one of the foremost approaches to cancer drug discovery in the future. Furthermore, the synthetic lethal interaction could eradicate the precursors of tumor cells, holding promise to become a unified modality for both cancer prevention and therapy in the future.”, said Dr. Yang.

?

To cap it off, Dr. Yang also presented the exciting progress that MBICR has made in the identification of plants that have synthetic lethal interactions with one or more types of oncogenic alterations. At last, he expressed his eagerness to advance these herbal precision therapeutics to clinical testing.

?

?

The distinguished speakers at the 1st?DNA Leaf Precision Oncology Symposium and their speech titles are listed at following.

?

Professor J. Michael Bishop, Nobel Laureate and Chancellor Emeritus, University of California, San Francisco

Personalized/Precision Medicine and Cancer

?

Professor Scott Kogan, University of California, San Francisco

Reconsidering Carcinogenesis in the Age of Epigenetics

?

Professor Alana Welm,?University of Utah

Patient-derived Xenografts and Organoids to Predict Therapeutic Response for Breast Cancer Patients

?

Dr. Dana Aftab, SVP of Exelixis

Phase III Trial of c-MET Inhibitor Cabozantinib in Hepatocellular Carcinomas

?

Professor Steven Cheng, Nanjing Medical University

Medulloblastoma, Hedgehog and Pathway to Precision Medicine

?

Professor Dean Felsher, Stanford University

Modeling and Predicting Oncogene Addiction

?

Dr. Na Li, Suining Central Hospital

The Clinical Application of Liquid Biopsy in the era of Precision Oncology

?

Dr. Dun Yang, Director of the J. Michael Bishop Institute of Cancer Research

Identification of Synthetic Lethal Agents from Natural Products Libraries for the Personalized Treatment of Cancer